Juvenile Polyposis Syndrome (JPS)

Juvenile polyps are hamartomatous lesions in the gastrointestinal (GI) tract with a distinct histological appearance of normal epithlium with cystic glands embedded in hyperplastic stroma and inflammatory infiltrate. Juvenile polyps are typically benign, but in individuals with juvenile polyposis syndrome (JPS), there is a 9-68% risk for malignant transformation (Howe et al., 1998). JPS is defined by either the presence of more than five juvenile polyps in the colorectum, or multiple juvenile polyps throughout the GI tract, or any number of juvenile polyps and a positive family history. Clinical features associated with other hamartomatous polyposis syndromes (i.e. PTEN-related disorders, Gorlin syndrome) are not present in JPS. Mutations in both the BMPR1A and SMAD4 genes are known to be causative of JPS. There are no strong genotype-phenotype correlations, although gastric polyps are more frequently observed in patients with SMAD4 gene mutations. Mutations in the SMAD4 gene are also associated with a juvenile polyposis syndrome-hereditary hemorrhagic telangiectasia (JPS-HHT) phenotype. Once again, the genotype alone can not predict the phenotype as the same SMAD4 mutations have been reported in patients with isolated JPS as well as JPS-HHT (Gallione et al., 2010). A contiguous gene deletion syndrome including the BMPR1A gene and the neighboring PTEN gene on chromosome 10q has been reported in association with juvenile polyposis of infancy, characterized by its early onset and presence of polyps throughout the GI tract. Additionally, macrocephaly, digital clubbing, and hypotonia have been observed in these patients. Prognosis is generally poor.

Tests Available

Forms and Documents

Test Details

BMPR1A, SMAD4
  • Confirmation of a clinical diagnosis
  • Differentiation of JPS from other hereditary hamartomatous polyposis syndromes (PTEN-related disorders, Gorlin syndrome)
  • Identification of family members at-risk for juvenile polyposis
  • To determine an appropriate surveillance and treatment protocol
  • Prenatal diagnosis in families with a known mutation
  • Exon Array CGH

Ordering

538
3-4 weeks
2-5 mL Blood - Lavender Top Tube
Oral Rinse (30-40 mL)|Buccal Swabs

Billing

81405x1, 81479x1
No
Yes
  • 211.3 Colon Appendix Cecum Ileocecal valve Large intestine NOS Excludes: benign carcinoid tumors of the large intestine (209.50-209.56) rectosigmoid junction (211.4)
  • 448.0 Hereditary hemorrhagic telangiectasia Rendu-Osler-Weber disease
* For price inquiries please email zebras@genedx.com

References

  1. Aretz et al., (2007) J Med Genet 44:702-709.
  2. Gallione et al., (2010) Am J Med Genet Part A 152A:333-339.
  3. Howe et al., (1998) Science 280:1086-1088.
  4. Van Hattem et al., (2008) Gut 57:623-627.

Forms and Documents

Test Details

BMPR1A, SMAD4
  • Confirmation of a clinical diagnosis
  • Differentiation of JPS from other hereditary hamartomatous polyposis syndromes (PTEN-related disorders, Gorlin syndrome)
  • Identification of family members at-risk for juvenile polyposis
  • To determine an appropriate surveillance and treatment protocol
  • Prenatal diagnosis in families with a known mutation
  • Capillary Sequencing
  • Exon Array CGH

Ordering

536
6-7 weeks
2-5 mL Blood - Lavender Top Tube
Oral Rinse (30-40 mL)|Buccal Swabs

Billing

81405x1, 81406x1, 81479x1
No
Yes
  • 211.3 Colon Appendix Cecum Ileocecal valve Large intestine NOS Excludes: benign carcinoid tumors of the large intestine (209.50-209.56) rectosigmoid junction (211.4)
  • 448.0 Hereditary hemorrhagic telangiectasia Rendu-Osler-Weber disease
* For price inquiries please email zebras@genedx.com

References

  1. Howe et al., (1998) Science 280:1086-1088.
  2. Van Hattem et al., (2008) Gut 57:623-627.
  3. Aretz et al., (2007) J Med Genet 44:702-709.
  4. Gallione et al., (2010) Am J Med Genet Part A 152A:333-339.

Forms and Documents

Test Details

BMPR1A
  • Confirmation of a clinical diagnosis
  • Differentiation of JPS from other hereditary hamartomatous polyposis syndromes (PTEN-related disorders, Gorlin syndrome)
  • Identification of family members at-risk for juvenile polyposis
  • To determine an appropriate surveillance and treatment protocol
  • Prenatal diagnosis in families with a known mutation
  • Capillary Sequencing

Ordering

537
3 weeks
2-5 mL Blood - Lavender Top Tube
Oral Rinse (30-40 mL)|Buccal Swabs

Billing

81479x1
No
Yes
  • 211.3 Colon Appendix Cecum Ileocecal valve Large intestine NOS Excludes: benign carcinoid tumors of the large intestine (209.50-209.56) rectosigmoid junction (211.4)
  • 448.0 Hereditary hemorrhagic telangiectasia Rendu-Osler-Weber disease
* For price inquiries please email zebras@genedx.com

References

  1. Aretz et al., (2007) J Med Genet 44:702-709.
  2. Gallione et al., (2010) Am J Med Genet Part A 152A:333-339.
  3. Howe et al., (1998) Science 280:1086-1088.
  4. Van Hattem et al., (2008) Gut 57:623-627.

Forms and Documents

Test Details

BMPR1A, SMAD4
  • An individual with multiple Juvenile polyps of the colon and/or throughout the GI tract (Of note: the term juvenile refers to the histopathology of the polyp, not the age at presentation)
  • An individual with any number of juvenile polyps and a family history of Juvenile polyposis syndrome
  • An individual with any number of polyps (juvenile or pathology unspecified) in addition to a personal history suggestive of hereditary hemorrhagic telangiectasia (HHT)
  • An unaffected individual with a family history suggestive of Juvenile polyposis syndrome (see above) when an affected individual is unavailable for his or her own genetic testing
  • Capillary Sequencing
  • Exon Array CGH

Ordering

717
3 weeks
2-5 mL Blood - Lavender Top Tube
Buccal Swab | Fibroblasts (separate charge for cell culture may apply) | Oral Rinse

Billing

81405x1, 81406x1, 81479x1
No
Yes
  • 211.3 Colon Appendix Cecum Ileocecal valve Large intestine NOS Excludes: benign carcinoid tumors of the large intestine (209.50-209.56) rectosigmoid junction (211.4)
  • 448.0 Hereditary hemorrhagic telangiectasia Rendu-Osler-Weber disease
* For price inquiries please email zebras@genedx.com

References

  1. Aretz et al., (2007) J Med Genet 44:702-709.
  2. Gallione et al., (2010) Am J Med Genet Part A 152A:333-339.
  3. Aretz et al., (2007) J Med Genet 44:702-709.
  4. Van Hattem et al., (2008) Gut 57:623-627.